Related Experiment Video
Updated: May 28, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Prevalence of Connective Tissue Disorder-Associated Interstitial Lung Disease Misdiagnosed and Treated As
Gaurav Sahu1, Tanushree Kothari1, Nensi Singh1
1Pulmonary Medicine, LN Medical College and Research Center and JK Hospital, Bhopal, IND.
Introduction:
Connective tissue disease-associated interstitial lung disease (CTD-ILD) is an important contributor to the burden of diffuse parenchymal lung disease in India. In tuberculosis-endemic regions, overlapping clinical and radiological features frequently result in misdiagnosis as pulmonary tuberculosis and exposure to empirical anti-tubercular therapy (ATT), leading to delayed initiation of appropriate treatment.
Methods:
We conducted a retrospective observational study of 17 patients diagnosed with CTD-ILD between July 2024 and July 2025 at a tertiary care center in Central India. Data collected included demographic characteristics, connective tissue disease subtype, high-resolution CT (HRCT) pattern, autoantibody profile, spirometry findings, prior exposure to anti-tubercular therapy, and treatment received.
Results:
The mean age was 52.7 years, with female predominance. Connective tissue disease subtypes included Sjögren syndrome (4/17, 24%), systemic lupus erythematosus (3/17, 18%), inflammatory myositis (3/17, 18%), systemic sclerosis (2/17, 12%), mixed connective tissue disease (3/17, 18%), and overlap syndromes (2/17, 12%). The HRCT patterns showed nonspecific interstitial pneumonia (NSIP) in 11/17 (65%), usual interstitial pneumonia (UIP) in 5/17 (29%), and lymphocytic interstitial pneumonia (LIP) in 1/17 (6%). All patients were positive for antinuclear antibodies, with disease-specific extractable nuclear antigen antibodies including Ro52, Jo-1, and Scl-70. Nine patients (9/17, 53%) had received empirical anti-tubercular therapy prior to diagnosis. Spirometry was available in 7/17 patients (41%); the median forced vital capacity was 75% of predicted, and the mean forced expiratory volume in one second to forced vital capacity ratio was 66%. Treatment included mycophenolate mofetil (9/17, 53%) and nintedanib (7/17, 41%), and one patient each received cyclophosphamide and rituximab, respectively.
Conclusions:
In this central Indian cohort, CTD-ILD most commonly presented with an NSIP pattern and was frequently misdiagnosed as tuberculosis, resulting in exposure to empirical anti-tubercular therapy. Early evaluation with HRCT and autoimmune serological testing is essential to ensure accurate diagnosis and timely initiation of appropriate immunosuppressive and antifibrotic therapy.
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...